~~<i id='9E658954DF'><strike id='9E658954DF'><tt id='9E658954DF'><pre id='9E658954DF'></pre></tt></strike></i>~~

Home» knowledge» explore

explore

author：knowledge 2025-10-06 10:21:20 Page View：54

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Paxlovid rebound happens. Why and to whom are still a mystery
Next article： After affirmative action ruling, medical educators look to 'holistic review'

explore

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Chemotherapy before breast cancer surgery might fuel metastasis

Abreastcancertumorimagedwithatechniquethathighlightsaspectsofitsmicroenvironment.NationalCancerInsti

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Lawmakers grill UnitedHealth CEO on Change cyberattack

KentNishimura/GettyImagesOnWednesday,UnitedHealthCEOAndrewWittyappearedbeforeCongresstoanswerforwhat